Monitor FDA acceptance and review timeline for the NDA; potential approval could significantly expand ORPATHYS's addressable market beyond China. Also watch for SANOVO Phase III results in treatment-naïve patients presented at ESMO.
Price Chart
Executive Summary
HUTCHMED announced positive Phase III SAFFRON trial results for ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) in MET-driven EGFR-mutated NSCLC after progression on TAGRISSO. The combination reduced the risk of disease progression or death by 45% and the risk of death by 32%, with a median OS extension of 4.9 months. An NDA has been submitted to the FDA for this combination.
Key Facts
- SAFFRON Phase III trial met primary endpoint of PFS (HR 0.55, p<0.001) and key secondary endpoint of OS (HR 0.68, p=0.010).
- Median PFS: 7.6 months (combination) vs 5.4 months (chemotherapy).
- Median OS: 17.8 months vs 12.9 months, a 4.9-month improvement.
- Results presented at ESMO Presidential Symposium and published in NEJM.
- NDA submitted to FDA for ORPATHYS plus TAGRISSO in this indication.
- Safety profile manageable and consistent with known profiles; Grade 3+ AEs 64% vs 63%.
- ORPATHYS is jointly developed by AstraZeneca and HUTCHMED, commercialized by AstraZeneca.
Financial Impact
Positive Phase III data and NDA submission for a combination targeting a large unmet need in EGFR-mutated NSCLC; potential to become a new standard of care. Market cap $2.5B.
Risk Factors
- FDA may require additional data or issue a Complete Response Letter (CRL).
- Competition from other MET-targeted therapies or emerging resistance mechanisms.
- Commercial uptake depends on biomarker testing adoption and reimbursement.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3387782 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | $15.41 | awaiting T+20 | — | $14.27 (−7.40%) |
Oct 26, 2026 today | Press Release | $14.50 | awaiting T+20 | — | $14.27 (−1.59%) |
Oct 26, 2026 1d ago | Press Release | $14.34 | awaiting T+20 | — | $14.27 (−0.49%) |
Oct 21, 2026 5d ago | 6-K | $14.37 | awaiting T+20 | — | $14.27 (−0.70%) |
Sep 29, 2026 27d ago | 6-K | $14.15 | awaiting T+20 | — | $14.27 (+0.85%) |
Sep 28, 2026 28d ago | 6-K | $14.15 | awaiting T+20 | — | $14.27 (+0.85%) |
Sep 29, 2026 28d ago | Press Release | $14.63 | awaiting T+20 | — | $14.27 (−2.46%) |
Sep 24, 2026 4w ago | 6-K | $13.90 $14.28 | ▲ +2.73% | ▲ +3.15% | $14.27 (+2.66%) |
Sep 24, 2026 4w ago | Press Release | $13.94 $14.36 | ▲ +3.01% | ▲ +4.49% | $14.27 (+2.37%) |
Sep 3, 2026 7w ago | 6-K | $14.11 $14.20 | ▲ +0.64% | ▲ +1.83% | $14.27 (+1.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers